Dr Just Genius - Senior Clinical Development Consultant

Q: Where is Dr Just based?

Dr Just is based in Brühl, Germany and can operate in on-site , hybrid , and remote work models.

Q: What languages does Dr Just speak?

Dr Just speaks the following languages: German (Native), English (Native), French (Intermediate) .

Q: How many years of experience does Dr Just have?

Dr Just has at least 21 years of experience. During this time, Dr Just has worked in at least 7 different roles and for 8 different companies . The average length of individual experience is 2 years and 8 months . Note that Dr Just may not have shared all experience and actually has more experience.

Q: What is Dr Just's latest experience?

Dr Just's most recent position is Senior Clinical Development Consultant at Syndeio Biosciences .

Q: What companies has Dr Just worked for in recent years?

In recent years, Dr Just has worked for Syndeio Biosciences , BioNTech , Genius Biotech Solutions Ltd , AC Immune , and UCB .

Q: Which industries is Dr Just most experienced in?

Dr Just is most experienced in industries like Pharmaceutical , Healthcare , and Education . Dr Just also has some experience in Biotechnology .

Q: Which business areas is Dr Just most experienced in?

Dr Just is most experienced in business areas like Research and Development (R&D) , Product Development , and Legal and Compliance . Dr Just also has some experience in Strategy and Planning and Operations .

Q: Which industries has Dr Just worked in recently?

Dr Just has recently worked in industries like Pharmaceutical and Biotechnology .

Q: Which business areas has Dr Just worked in recently?

Dr Just has recently worked in business areas like Product Development , Research and Development (R&D) , and Strategy and Planning .

Recommended expert

Brühl, Germany

Experience

Jul 2025 - Present

8 months

Senior Clinical Development Consultant

Syndeio Biosciences

Leading all clinical, regulatory and translational aspects of a novel NMDAR-PAM for Alzheimer’s disease and in undisclosed rare diseases.

Jun 2022 - Jul 2023

1 year 2 months

Senior Clinical Consultant

BioNTech

Established comprehensive indication strategy for a TNFR2 agonist, including translational strategy and clinical design options focusing on neurodegeneration and regeneration.
Managed KOL and CRO relationships and competitive intelligence.
Developed a score-based methodology to optimize indication selection across neurology, inflammation and fibrotic disorders, enabling critical decision-making on entering the neurology space.

Sep 2021 - Present

4 years 6 months

Valletta, Malta

Founder and CEO

Genius Biotech Solutions Ltd

Consulting biotechnology and pharma companies with a focus on early clinical development.
Providing strategic leadership across end-to-end clinical planning and execution under FDA regulations, including safety oversight, CRO selection and governance, biomarker strategy, KOL and site management, and regulatory strategy through FDA IND preparation and submission.
Applying clinical and scientific background in neurology and psychiatry, including neurodegenerative disorders, neuroinflammatory disorders, brain and spinal cord trauma, major depression, schizophrenia and neuropediatric disorders, plus gastrointestinal inflammatory disorders, autoimmune disease and fibrotic disorders.
Managing external stakeholders such as key opinion leaders, patient advocacy groups and regulatory authorities.
Providing a scientific and business basis for strategic decisions and ensuring efficient team management and communication skills.

Aug 2021 - Jul 2024

3 years

Senior Clinical Development Consultant

AC Immune

Generated clinical protocols and translational strategies for an active Parkinson’s vaccination program and an early-stage FTD/ALS program (therapeutic antibody and novel PET-tracer).
Developed strategy and translational planning for an early-stage program on morphomers for tauopathies (AD and PSP).
Contributed to clinical development and translational plan for a novel antiinflammatory compound targeting non-alcoholic liver fibrosis.
Developed a dedicated tool to benchmark potential target indications for strategic portfolio decisions, exploring orphan and fibrotic disorder indications with scientific rationale, feasibility, regulatory strategy and safety, and conducted competitive intelligence.
Led the clinical work-package for digital transformation using novel wearable technologies, computational biology and artificial intelligence to optimize signal detection in clinical trials.

Jan 2019 - Dec 2021

3 years

Brussels, Belgium

Senior Medical Director, Neurology Development

UCB

Served as medical lead for an early phase clinical development program in Parkinson’s disease (ORCHESTRA study), achieving successful transition into Phase II.
Led an international multidisciplinary team, including clinicians, translational scientists, regulatory experts, biostatisticians, operational experts and commercial leads, to transition an asset into Phase II ahead of schedule.
Managed site selection and oversight, CRO benchmarking, study startup and safety monitoring for Phase I.
Coordinated design of translational and analytical plans and led filing activities and FDA meetings.
Co-developed a device/AI based trial strategy with Neuropore and Verily and implemented it in a Phase II trial.
Selected and managed KOLs and advisory boards and conducted investigator and site selection.
Contributed to development of a novel PRO instrument for Parkinson’s disease outcome measures.
Led publication strategy as main senior author for core publications, posters and presentations.
Designed hybrid trial plans to overcome COVID-19 challenges.
Led translational strategy implementation of digital biomarkers and artificial intelligence in neurology development activities.
Supported pipeline reshaping for neurodegeneration and neuroinflammation and identified alternative target indications.
Contributed to biomarker consortia as Steering Committee member for the FNIH Neuroscience Steering Committee of the Biomarkers Consortium.
Served as medical lead for a discovery stage gene therapy program in FTD preparing candidate selection and transition into FIH.

Oct 2014 - Dec 2018

4 years 3 months

Chicago, United States

Medical Director and Head of Translational Biology

AbbVie

Acted as main interface between Neuroscience Discovery and Clinical Development to bridge gaps, streamline processes and optimize budget decisions.
Served as clinical lead for AbbVie-Calico collaboration on vanishing white matter disease and other rare diseases, initiating development programs.
Led first-in-human and early-stage drug development for progressive MS (anti-RGMa) and spinal cord injury, including IND submission, trial design, translational plan generation and safety monitoring.
Led development of a PET imaging technology to assess residual inflammation in Crohn’s disease and validated mitochondrial activity tracers.
Initiated and led a glycobiology team to establish a microarray platform and evaluate small molecules modulating cell surface glycan composition for neurodegeneration, neuroinflammation, vascular diseases and fibrosis, with adoption by AbbVie in neurology and oncology.
Founded and co-led a project optimizing antibody targeting via specific protein glycoforms.
Provided managerial direction and clinical/scientific guidance to early-stage drug development/discovery across neurology, gastrointestinal inflammatory disorders and fibrosis.
Managed one direct report and a global matrix team.
Oversaw clinical safety for multiple Phase 0 and Phase 1 studies in immunology, gastroenterology and neurosciences.
Implemented biomarkers for enrichment and novel clinical endpoints in progressive MS, AD and PD, including nonconventional MR imaging, PET, OCT and biochemical tools.
Served as translational lead for calpain inhibitor and S1P5 antagonist exploration.
Developed a communication strategy for early patient access in rare diseases.
Explored business options and clinical-translational plans for genetic neuropediatric orphan diseases.
Supported clinical development strategies in MS and alternative indications (spinal cord injury, AD, ALS, FTD, LHON, Huntington, neuropaediatric storage disorders and leukencephalopathies) by identifying KOLs, designing development scenarios and forming advisory boards.
Assessed in-licensing opportunities for MS, AD, PD, ALS and retinal diseases under aggressive timelines for AbbVie and AbbVie-Calico collaboration.
Participated in regulatory consortia to promote acceptance of novel biochemical biomarkers in AD and MS (e.g., ADNI-PPSB, CAMD).
Scouted novel technologies, including imaging and blood/CSF biomarkers, for ongoing development programs.
Established partnerships with US MS study sites, handling selection, training, surveillance and document authoring (IND/IRB).
Led teams responsible for safety reports and data presentations to monitoring boards, FDA and regulatory authorities.

Feb 2012 - Sep 2014

2 years 8 months

Essen, Germany

Clinical Research Assistant (Psychiatry) and Research Group Lead

University of Duisburg-Essen

Founded and led the experimental research section “Environmental Stress and Neurodegeneration.”
Supervised multiple PhD and MD students.
Established and managed a biobank for neurodegenerative disorders.
Set up and led a laboratory for advanced confocal live cell imaging in in vitro Alzheimer’s models.
Focused on excitotoxic mechanisms in AD, FTD, ALS, TBI and other neurodegenerative disorders.
Initiated projects to assess and validate potential Alzheimer’s CSF biomarker candidates in collaboration with industry partners.
Contributed to clinical work packages in international biomarker consortia (JPND-BIOMARKAPD, PURE).
Served as clinical lead for nanotechnology diagnostics in the EU NADINE nanobiotechnology project.

Feb 2004 - Dec 2011

7 years 11 months

Resident Physician and Researcher

Ludwig-Maximilians-University Munich

Conducted research on the molecular background of schizophrenia and neurogenetics, securing substantial third-party funding.
Received a German-Israeli Foundation grant to study the MOA of riluzole in ALS.
Obtained grants to investigate NMDA and mGlu receptor dysfunction in neurodegenerative diseases and schizophrenia.
Implemented new translational in vivo and in vitro models for schizophrenia.
Trained in Dialectical Behavior Therapy (DBT) and suicide intervention.
Served as sub-investigator in clinical studies on anti-dementia therapies, including vaccination and neurochemical/imaging biomarker studies.
Tutored neurology and psychiatry students within the Munich-Harvard Teaching Alliance and MECUM Program.
Supervised multiple MD and PhD students independently.
Acted as psychiatric expert witness in high-profile criminal and civil cases.
Gained extensive teaching experience through seminars and bedside teaching.

Summary

Physician-scientist (MD) and senior clinical development leader with 11+ years in biotech/pharma and 45+ peer-reviewed publications. Founder/CEO of Genius Biotech Solutions providing end-to-end early clinical development leadership (FIH/Phase 1–2 strategy, IND/CTA readiness, CRO selection/oversight, safety monitoring, biomarker and translational strategy, KOL/site engagement). Deep expertise in neurology and psychiatry with primary focus on neurodegeneration (Alzheimer’s, Parkinson’s, MS, FTD/ALS) and rare CNS disorders, plus experience in inflammation/fibrosis. Proven track record leading global cross-functional teams, regulatory interactions, and innovative endpoint strategies integrating imaging, biofluid, digital and AI-enabled biomarkers.

Languages

German

Native

English

Native

French

Intermediate

Education

Oct 1994 - Jun 2001

Medical University of Lübeck

M.D. Medicine · Medicine · Lübeck, Germany · 1.0 (Overall grade of the German Medical State Examination)

Profile

Created

February 2026

Need a freelancer? Find your match in seconds.

Try FRATCH GPT

Frequently asked questions

Do you have questions? Here you can find further information.

Where is Dr Just based?

Dr Just is based in Brühl, Germany and can operate in on-site, hybrid, and remote work models.

What languages does Dr Just speak?

Dr Just speaks the following languages: German (Native), English (Native), French (Intermediate).

How many years of experience does Dr Just have?

Dr Just has at least 21 years of experience. During this time, Dr Just has worked in at least 7 different roles and for 8 different companies. The average length of individual experience is 2 years and 8 months. Note that Dr Just may not have shared all experience and actually has more experience.

What roles would Dr Just be best suited for?

Based on recent experience, Dr Just would be well-suited for roles such as: Senior Clinical Development Consultant, Senior Clinical Consultant, Founder and CEO.

What is Dr Just's latest experience?

Dr Just's most recent position is Senior Clinical Development Consultant at Syndeio Biosciences.

What companies has Dr Just worked for in recent years?

In recent years, Dr Just has worked for Syndeio Biosciences, BioNTech, Genius Biotech Solutions Ltd, AC Immune, and UCB.

Which industries is Dr Just most experienced in?

Dr Just is most experienced in industries like Pharmaceutical, Healthcare, and Education. Dr Just also has some experience in Biotechnology.

Which business areas is Dr Just most experienced in?

Dr Just is most experienced in business areas like Research and Development (R&D), Product Development, and Legal and Compliance. Dr Just also has some experience in Strategy and Planning and Operations.

Which industries has Dr Just worked in recently?

Dr Just has recently worked in industries like Pharmaceutical and Biotechnology.

Which business areas has Dr Just worked in recently?

Dr Just has recently worked in business areas like Product Development, Research and Development (R&D), and Strategy and Planning.

What is Dr Just's education?

Dr Just holds a Doctorate in Medicine from Medical University of Lübeck.

What is the availability of Dr Just?

Dr Just is immediately available full-time for suitable projects.

What is the rate of Dr Just?

Dr Just's rate depends on the specific project requirements. Please use the Meet button on the profile to schedule a meeting and discuss the details.